Clinerion is now part of Citeline
Clinerion has been integrated into New York-based company Citeline. Clinerion plans to expand its portfolio with Citeline’s complementary opportunities with regard to drug development acceleration. Clinerion’s headquarters are to remain in Basel.
Clinerion’s CEO Barış Erdoğan has officially announced that the company is now part of Citeline, a leader in clinical trials. The company based in New York, which formerly operated as Pharma Intelligence, merged with Norstella from the US state of Pennsylvania at the end of 2022. This means that the Norstella Group now comprises five companies: Evaluate, MMIT, Panalgo, The Dedham Group, and Citeline.
The new pharmaceutical technology company with more than 1,600 employees across the world is now one of the world’s largest providers of pharma information solutions on the market. According to a press release from Norstella, it is currently valued at 5 billion US dollars. It aims to enable smooth access to life-saving therapies for those with illnesses by accompanying life science companies throughout the entire drug development process.
Clinerion’s headquarters remain in Basel
According to a personal message from Clinerion’s CEO, its integration into Citeline provides the opportunity to access tools and services that each supplement the other’s, thus expanding the product portfolio. Furthermore, Clinerion will gain access to specialists and expertise along the entire process chain from clinical intelligence, planning, development, and studies. This is why the merger with Citeline and the Norstella Group is “excellent news” for partners and customers. Clinerion’s headquarters will remain in Basel.